Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

BCTX - BriaCell Therapeutics Corp. Последние... | Finranks

Home

BCTX

(BCTX)

NCM – Цена в реальном времени. Валюта: USD

3.75

-0.14 (-3.60%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

3.86

+0.11 (2.93%)

После закрытия: Mar 27, 2026, 7:40 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it will present four posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612 ), two posters highlighting further analyses of Phase 2 data, and one poster presenting preclinical data related to Bria-OTS+, BriaCell's next-generation personalized off-the-shelf immunotherapy for cancer. Abstracts will be published in the online Proceedings of the AACR.

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA. The accepted abstracts highlight research related to BriaCell's cellular immunotherapy platform, including the Company's ongoing pivotal Phase 3 study of Bria-IMT ᵀᴹ in combination with an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612) and research supporting Bria-OTS+ ᵀᴹ , BriaCell's next-generation personalized off-the-shelf immunotherapy program.

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX , BCTXL ) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2025 held on March 5, 2026 (the “Meeting”). A total of 48.31% of the Company's issued and outstanding common shares (the “Common Shares”) were voted at the Meeting.

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that they have entered into a definitive purchase agreement (the “Purchase Agreement”) pursuant to which BriaPro has agreed to purchase BriaCell's exclusive license to develop and commercialize Soluble CD80 (“sCD80”) as a biologic agent for the treatment of cancer and other associated assets (the “Transaction”).

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, releases new images highlighting resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvement. Survival details on these and other select patients in its Phase 2 study, along with comparable populations, were previously reported.

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations No Bria-IMT™ related discontinuations reported to date Bria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in 9 cases as of their last assessment. Table 1: Ongoing Long-Term Survivors Patient/Subtype Months Since Study Start Age Number of Prior Regimens Cycles of Bria-IMT 01-009/ER+/PR+/HER2low 47 74 5 14 07-001/ER+/PR+/HER2low 30 55 7 8 15-001/ER+/PR-/HER2- 30 62 3 12 11-018/ER+/PR+/HER2+(Highlighted below) 27 66 8; including ENHERTU 35 15-005/ER+/PR+/HER2-(Highlighted below) 27 44 5 6 15-006/ER+/PR-/HER2-(Highlighted below) 25 64 8; including TRODELVY 4 15-004/ER+/PR+/HER2- 25 50 3 6 11-019/ER+/PR+/HER2low 23 63 9; including TRODELVY 6 07-014/ER+/PR+/HER2low >18 62 9; including TRODELVY 5 Note that Trodelvy and Enhertu are antibody-drug conjugates recently approved for late-stage breast cancer.

Видео

No Data

There is no data to display

Пресс-релизы

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX , BCTXL ) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2025 held on March 5, 2026 (the “Meeting”). A total of 48.31% of the Company's issued and outstanding common shares (the “Common Shares”) were voted at the Meeting.

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that they have entered into a definitive purchase agreement (the “Purchase Agreement”) pursuant to which BriaPro has agreed to purchase BriaCell's exclusive license to develop and commercialize Soluble CD80 (“sCD80”) as a biologic agent for the treatment of cancer and other associated assets (the “Transaction”).

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, releases new images highlighting resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvement. Survival details on these and other select patients in its Phase 2 study, along with comparable populations, were previously reported.